| Clinical data | |
|---|---|
| Other names | (9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C32H37NO12 |
| Molar mass | 627.643 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 188 to 192 °C (370 to 378 °F) (decomposes) |
| |
| |
| | |
Pirarubicin (INN) is ananthracycline drug.An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic thandoxorubicin and exhibits activity against some doxorubicin-resistant cell lines.[1]
Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |